Survival and morbidity outcomes for very low birth weight infants with down syndrome

Pediatrics

Volumn 126, Issue 6, 2010, Pages 1132-1140

  Boghossian, Nansi S ^a   Hansen, Nellie I ^b   Bell, Edward F ^a   Stoll, Barbara J ^c,d   Murray, Jeffrey C ^a   Laptook, Abbot R ^e   Shankaran, Seetha ^f   Walsh, Michele C ^g   Das, Abhik ^b   Higgins, Rosemary D ^h  

^a UNIVERSITY OF IOWA   (United States)

^b RTI INTERNATIONAL   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^e BROWN UNIVERSITY   (United States)

^f WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Down syndrome; Neonatal morbidity; Neonatal mortality; Preterm infants; Trisomy 21

Indexed keywords

ARTICLE; CHROMOSOME ABERRATION; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; HUMAN; INFANT; INFANT MORTALITY; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; NECROTIZING ENTEROCOLITIS; OUTCOME ASSESSMENT; PATENT DUCTUS ARTERIOSUS; PERINATAL MORBIDITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROLENTAL FIBROPLASIA; RISK ASSESSMENT; RISK FACTOR; SEPSIS; SURVIVAL; VERY LOW BIRTH WEIGHT;

ADULT; DOWN SYNDROME; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT MORTALITY; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT; MALE; MORBIDITY; PREGNANCY; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 78649670326     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-1824     Document Type: Article

References (29)

1. Sherman SL, Allen EG, Bean LH, Freeman SB. Epidemiology of Down syndrome. Ment Retard Dev Disabil Res Rev. 2007;13(3):221-227
2. Zorick TS, Mustacchi Z, Bando SY, et al. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur J Hum Genet. 2001;9(11):811-814
3. Ryoo SR, Jeong HK, Radnaabazar C, et al. DYRK1A-mediated hyperphosphorylation of Tau: a functional link between Down syndrome and Alzheimer disease. J Biol Chem. 2007;282(48):34850-34857
4. Murdoch JC, Rodger JC, Rao SS, Fletcher CD, Dunnigan MG. Down's syndrome: an atheroma-free model? Br Med J. 1977;2(6081):226-228
5. Fulcher T, Griffin M, Crowley S, Firth R, Acheson R, O'Meara N. Diabetic retinopathy in Down's syndrome. Br J Ophthalmol. 1998;82(4):407-409
6. Satgé D, Sasco AJ, Carlsen NL, et al. A lack of neuroblastoma in Down syndrome: a study from 11 European countries. Cancer Res. 1998;58(3):448-452
7. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. 2000;355(9199):165-169
8. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet. 2002;359(9311):1019-1025
9. Greene AK, Kim S, Rogers GF, Fishman SJ, Olsen BR, Mulliken JB. Risk of vascular anomalies with Down syndrome. Pediatrics. 2008;121(1). Available at: www.pediatrics.org/cgi/content/full/121/1/e135
10. Corsi MM, Dogliotti G, Pedroni F, et al. Adipocytokines in Down's syndrome, an atheroma-free model: role of adiponectin. Arch Gerontol Geriatr. 2009;48(1):106-109
11. Rabin KR, Whitlock JA. Malignancy in children with trisomy 21. Oncologist. 2009;14(2):164-173
12. Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M. A United States national reference for fetal growth. Obstet Gynecol. 1996;87(2):163-168 (Pubitemid 26033124)
13. Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal necrotizing enterocolitis: therapeutic decisions based upon clinical staging. Ann Surg. 1978;187(1):1-7
14. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702-706 (Pubitemid 38405384)
15. Heron M, Sutton PD, Xu J, Ventura SJ, Strobino DM, Guyer B. Annual summary of vital statistics: 2007. Pediatrics. 2010;125(1):4-15
16. Canfield MA, Honein MA, Yuskiv N, et al. National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001. Birth Defects Res A Clin Mol Teratol. 2006;76(11):747-756
17. Dees E, Lin H, Cotton RB, Graham TP, Dodd DA. Outcome of preterm infants with congenital heart disease. J Pediatr. 2000;137(5):653-659
18. Tanner K, Sabrine N, Wren C. Cardiovascular malformations among preterm infants. Pediatrics. 2005;116(6). Available at: www.pediatrics.org/cgi/content/ full/116/6/e833
19. Shin M, Besser LM, Kucik JE, et al. Prevalence of Down syndrome among children and adolescents in 10 regions of the United States. Pediatrics. 2009;124(6):1565-1571
20. Myrelid A, Gustafsson J, Ollars B, Anneren G. Growth charts for Down's syndrome from birth to 18 years of age. Arch Dis Child. 2002;87(2):97-103
21. Agha MM, Williams JI, Marrett L, To T, Dodds L. Determinants of survival in children with congenital abnormalities: a long-term populationbased cohort study. Birth Defects Res A Clin Mol Teratol. 2006;76(1):46-54 (Pubitemid 43227677)
22. Linhart Y, Bashiri A, Maymon E, et al. Congenital anomalies are an independent risk factor for neonatal morbidity and perinatal mortality in preterm birth. Eur J Obstet Gynecol Reprod Biol. 2000;90(1):43-49
23. Wallace DK, Kylstra JA, Phillips SJ, Hall JG. Poor postnatal weight gain: a risk factor for severe retinopathy of prematurity. J AAPOS. 2000;4(6):343-347
24. Hellström A, Ley D, Hansen-Pupp I, et al. New insights into the development of retinopathy of prematurity: importance of early weight gain. Acta Paediatr. 2010;99(4):502-508
25. May CA, Ohlmann AV, Hammes H, Spandau UH. Proteins with an endostatin-like domain in a mouse model of oxygen-induced retinopathy. Exp Eye Res. 2006;82(2):341-348 (Pubitemid 43122121)
26. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88(2):277-285 (Pubitemid 28015876)
27. Baek KH, Zaslavsky A, Lynch RC, et al. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature. 2009;459(7250):1126-1130
28. De La Torre R, Casado A, Lopez-Fernandez E, Carrascosa D, Ramirez V, Saez J. Overexpression of copper-zinc superoxide dismutase in trisomy 21. Experientia. 1996;52(9):871-873
29. Spierer A, Rabinowitz R, Pri-Chen S, Rosner M. An increase in superoxide dismutase ameliorates oxygen-induced retinopathy in transgenic mice. Eye (Lond). 2005;19(1):86-91 (Pubitemid 40192646)